Biostimulator for the tear trough: indication and risks
"I want a biostimulator in my under-eye area" is a request that appears more and more in the office, often with the name of a specific product. The idea seems logical to the patient: if the biostimulator improves the skin of the face, it should improve the thin skin under the eyes. For the professional, the answer comes down to three questions: what the product's instructions for use say about the area, what kind of under-eye concern the patient has, and what happens if something goes wrong in a place where nothing can be easily removed.
This guide is a review. The classification of under-eye concerns is in dark circles: types and assessment and the comparison between biostimulator classes is in biostimulators: overview. There are no doses, dilutions or technique: those are decisions for the qualified professional, according to the product registration and the rules of their professional council.
What do the instructions for use say?
This is the point that weighs the most. In the biostimulator instructions for use consulted, for calcium hydroxylapatite and for poly-L-lactic acid, the periorbital area does not appear among the approved indications, and there are warnings that safety and efficacy in that area have not been established. For poly-L-lactic acid, there is also a description of a higher risk of papules and nodules when used around the eyes.
The picture may vary between products and change over time. What counts is the instructions for use of the product you have in hand, in the version registered with ANVISA (Brazil's health regulatory agency).
Why is the periorbital area delicate for biostimulators?
| Feature of the area | Consequence for the biostimulator |
|---|---|
| Very thin skin with little subcutaneous tissue | Nodules and irregularities are visible and palpable |
| Orbicularis oculi muscle in constant motion | Movement may favor product accumulation |
| Delicate lymphatic drainage | Swelling tends to be more marked and longer lasting |
| Proximity to the orbit and anastomoses with the ophthalmic artery | Risk of vascular occlusion with ocular consequences |
| Biostimulators are not broken down by hyaluronidase | Excess, a nodule or a misplaced product cannot be quickly reversed |
The last row is decisive. With hyaluronic acid, excess or a nodule in the tear trough can be corrected with the enzyme. With a biostimulator, the measures described for nodules are slower and less predictable, and sometimes involve invasive procedures. In an area this visible, that weighs heavily on the decision.
What kind of under-eye concern does the patient have?
The word "dark circles" hides very different concerns. A biostimulator, even if it were indicated, would not address all of them:
| Type | What is behind it | Does a biostimulator help? |
|---|---|---|
| Pigmented | Excess melanin in the skin | No; calls for a pigment approach |
| Vascular | Vessels visible through thin skin | Does not resolve the vessel |
| Structural (groove) | Depression of the tear trough and the orbicular retaining ligament | The best-studied treatment is hyaluronic acid filler |
| Bag | Protrusion of the eyelid fat pads | No; injecting can worsen the bag; surgical assessment |
| Laxity and thin skin | Loss of eyelid skin quality | Other skin quality options are usually discussed |
| Mixed | A combination of the above | Depends on the main component |
In many patients, the complaint of a "hollow under-eye" is also a complaint of lost midface support. When the cheekbone loses volume and the SOOF descends, the transition between the eyelid and the cheek becomes marked. In these cases, some plans treat support in the neighboring areas, such as the cheekbone and the zygomatic area, and not the tear trough itself. That decision belongs to the professional, based on the assessment and on what each product's registration allows.
What are the best-studied alternatives?
| Concern | Approach usually discussed | Page |
|---|---|---|
| Tear trough groove | Hyaluronic acid filler, in a product and plane suited to the area | Tear trough filler |
| Lid-cheek transition | Lower eyelid smoothing and midface support | Lower eyelid smoothing |
| Eyelid skin quality | Skin quality options indicated for the area | Skinbooster in the under-eye area |
| Loss of midface support | Cheekbone volumization and, depending on the case, a biostimulator in the indicated areas | Cheekbone filler |
| Fat bag | Surgical assessment | Lower eyelid |
What risks should be considered if the topic comes up?
The risks described for biostimulators in the periorbital area include:
- Visible nodules and papules, which can appear weeks or months later and are hard to correct.
- Granuloma, a late inflammatory reaction described with biostimulators.
- Prolonged swelling, because of the area's delicate drainage.
- Contour irregularity in the lower eyelid.
- Vascular occlusion, with a risk of ocular compromise, with no possibility of breaking the product down with hyaluronidase.
What to do about each one is in nodules after a biostimulator and complications with biostimulators.
How to answer the patient who asks for a biostimulator in the tear trough?
The patient has usually seen a result on social media. Declining without explaining looks like unwillingness; explaining clearly usually builds trust.
If the decision is not to treat the tear trough, record the refusal and the reason. For documents, see general contraindications in HOF and the informed consent template for biostimulator, to be adapted and reviewed with a lawyer and with the rules of your professional council. For the patient's question about results and sessions, there is tear trough filler: results and sessions.
And in Harmy?
Checklist before considering a biostimulator near the eyes
- Instructions for use of the product checked for the periorbital area.
- Type of under-eye concern classified: pigment, vessel, groove, bag, laxity or mixed.
- Fat bag ruled out with the look-up test.
- Best-studied and reversible alternatives presented.
- Midface support assessed as a possible focus of the plan.
- Patient informed that a biostimulator is not broken down by hyaluronidase.
- Emergency protocol and referral ophthalmology service defined.
- Decision, including refusal, recorded in the patient record and in the consent.
Frequently asked questions
Can a biostimulator be injected into the tear trough?
In the biostimulator instructions for use consulted, the periorbital area generally does not appear among the indications, and there are warnings that safety there has not been established. The risk of visible nodules in thin skin is the main concern. Check the instructions for the registered product before any decision.
Is calcium hydroxylapatite safe in the under-eye area?
Calcium hydroxylapatite cannot be removed with hyaluronidase and, in thin skin like the eyelid, nodules tend to be visible. Instructions for use of products in this class state that safety in the periorbital area has not been established. The decision belongs to the qualified professional, according to the product registration.
Biostimulator or hyaluronic acid for the tear trough?
For the tear trough groove, hyaluronic acid has the advantage of being degradable with hyaluronidase in case of excess or complication. The biostimulator has no such option and is generally not indicated for the area in the instructions for use. In some plans, the biostimulator is used in neighboring areas, such as the cheekbone, and not in the tear trough itself.
Does a biostimulator improve dark circles?
It does not resolve pigment or visible vessels. Dark circles from pigment or vessels call for another diagnosis and other approaches. A biostimulator works on firmness and tissue quality, gradually.
Harmy images are illustrative simulations generated by AI from the patient's photo to support the conversation between practitioner and patient. They are not a promise of results. Indication, technique, product and volume are solely the decision of the licensed practitioner. This content is for information only and does not replace a clinical assessment.